Corbus Pharmaceuticals (CRBP) PT Raised to $58 at Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St futures rise on tech buying, Middle East peace hopes
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil falls as traders digest escalation in US-Iran strikes
- Oracle reports earnings today: Analysts say this metric could 'catalyze higher multiples'
- UBS sees generational semiconductor boom, highlights stock winners
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
- Wall Street indexes fall more than 1%, hit by tech, Iran war worries
- UBS sees generational semiconductor boom, highlights stock winners
Corbus Pharmaceuticals (CRBP) PT Raised to $52 at Jefferies
March 13, 2024 6:31 AM EDTJefferies analyst Maury Raycroft raised the price target on Corbus Pharmaceuticals (NASDAQ: CRBP) to $52.00 (from $46.00) while maintaining a Buy rating.
The analyst comments "We see two valuation drivers for CRBP currently: 1) CRB-701 Nectin-4 ADC & 2) obesity CB1 asset CRB-913; both could... More
